CAM
VNDA icon

Cormorant Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Cormorant Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-957,821
Closed -$18.2M – 68
2018
Q2 		$18.2M Hold
957,821
– – 1.35% 27
2018
Q1 		$16.1M Buy
+957,821
New +$16M 1.2% 20

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cormorant Asset Management's VNDA Position: Q3 2018 in Review

Cormorant Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2018, closing a stake of 957,821 shares — an estimated $18.2M sold.

Cormorant Asset Management first reported a position in VNDA in Q1 2018 and held it in 2 quarters. The position peaked at $18.2M in Q2 2018. 160 funds tracked by Wall St. Rank hold VNDA as of Q3 2018.

  • Cormorant Asset Management reported no remaining Vanda Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cormorant Asset Management sold 957,821 Vanda Pharmaceuticals shares in Q3 2018, an estimated $18.2M.
  • Cormorant Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Cormorant Asset Management's Vanda Pharmaceuticals position peaked at $18.2M in Q2 2018.
  • 160 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2018.

Based on Cormorant Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.